drugset / Trial / NCT00998036
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors
Phase 1
Completed
9 enrolled
Columbia University
Genentech, Inc. · collabWyeth is now a wholly owned subsidiary of Pfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I research study designed to determine the maximum tolerated dose (MTD) of cisplatin, temsirolimus, and erlotinib in combination for treatment in triple negative breast cancer (TNBC) patients.
Timeline
- Start
- 2009-09
- Primary completion
- 2012-06
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 30 mg/m2 | Intravenous |
| Subject | Erlotinib | Small molecule | 100 mg | Oral |
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Temsirolimus | Small molecule | 15 mg | Intravenous |
| Subject | Temsirolimus | Small molecule | 25 mg | Intravenous |